Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6-hydroxydopamine rat model.
The functional significance of the interhemispheric projections on the basal ganglia level is poorly understood. Insofar as the anatomical evidence for crossing projections between basal ganglia nuclei is sparse, whereas tracing studies demonstrated important crossing projections from the pedunculopontine nucleus (PPN) to the basal ganglia, it is suggested that the PPN might play a key role in interhemispheric regulation of basal ganglia activity. The present study was performed to assess changes in neuronal activity of ipsilateral and contralateral subthalamic nucleus (STN), substantia nigra pars reticulata (SNr), and PPN in the unilateral 6-hydroxydopamine (6-OHDA) rat model of advanced PD under urethane anesthesia. After unilateral lesioning of the SNc, the firing rate of contralateral STN neurons significantly increased from 10.9 +/- 1.0 spikes/sec (mean +/- SEM) to 16.3 +/- 1.5 spikes/sec. Similarly, the firing rate of contralateral SNr neurons significantly increased from 19.4 +/- 1.2 to 25.7 +/- 1.9 spikes/sec, and the firing rate of contralateral PPN neurons significantly increased from 10.6 +/- 0.8 to 13.9 +/- 1.1 spikes/sec. The observed activity changes in contralateral STN, SNr, and PPN are similar to those induced in the corresponding nuclei of the hemisphere ipsilateral to the nigrostriatal degeneration. Based on previous, predominantly anatomical data, the results of the present study suggest that the PPN on the lesioned side is at the origin of changes in the activity of STN and SNr on the contralateral hemisphere, because of its crossing efferent projections.
Breit
S
S
Center of Neurology and Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tübingen, Tübingen, Germany. sorin.breit@uni-tuebingen.de
Martin
A
A
Lessmann
L
L
Cerkez
D
D
Gasser
T
T
Schulz
J B
JB
D018663:Adrenergic Agents / Q000633:toxicity; D000818:Animals; D001479:Basal Ganglia / Q000378:metabolism* / Q000473:pathology; D004569:Electroencephalography; D007839:Functional Laterality / Q000502:physiology*; D007150:Immunohistochemistry; D008297:Male; D009434:Neural Pathways / Q000502:physiology*; D009474:Neurons / Q000378:metabolism* / Q000473:pathology; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley
D018663:Adrenergic Agents; D016627:Oxidopamine